Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Blood metabolite profiles and risk of developing breast cancer in PLCO.

Principal Investigator
Name
Steven Moore
Degrees
-
Institution
Extramural
Position Title
-
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2013-0255
Initial CDAS Request Approval
Nov 11, 2013
Title
Blood metabolite profiles and risk of developing breast cancer in PLCO.
Summary
Breast cancer risk is likely influenced by metabolic factors, but scientific knowledge on the subject is limited. Extensive pilot work by our group indicates that metabolomics is a reliable, robust, and potentially powerful tool for characterizing individual metabolic profiles. Herein, we propose a metabolomics analysis of ~600 metabolites in T1 serum samples from 550 postmenopausal breast cancer cases and 550 matched controls in PLCO not on menopausal hormone therapy at baseline. The study proposed is the second stage for our breast cancer metabolomics workwe have already conducted a metabolomics breast cancer study in postmenopausal women not on menopausal hormone therapy in the Shanghai Womens Health Study (SWHS: 333 cases, 333 controls; results enclosed). The proposed PLCO study will greatly enhance our statistical power to detect associations and will enable us to determine whether associations observed in an Asian population extend to a Western population and vice versa. We also propose to examine metabolic early markers of breast cancer in 200 of these cases by analyzing metabolic changes in serum samples collected proximal to disease, i.e. within the 3-36 months prior to diagnosis. We will compare changes in metabolite levels to changes in ~200 controls, using additional control samples collected at a similar point in follow-up. Analyses will be done using the liquid chromatography and gas chromatography mass spectrometry platforms of Metabolon Inc.
Aims

1. Examine each of ~600 identified metabolites and associated metabolic profiles in prediagnostic T1 serum in relation to subsequent breast cancer incidence

2. Examine metabolite levels and metabolic profiles in samples proximal to diagnosis in relation to breast cancer incidence

Collaborators

Robert Hoover (DCEG, OD)
Joshua Sampson (DCEG, BB)
Regina Ziegler (DCEG, OD)
Rashmi Sinha (DCEG, NEB)
Charles Matthews (DCEG, NEB)
Steven Moore (Extramural)
Mary Playdon (Huntsman Cancer Institute)
Yei-Eun Shin (NCI)

Related Publications